A Pilot Study of the Anti-SLAMF7 Monoclonal Antibody, Elotuzumab, in Patients With Myelofibrosis
Latest Information Update: 11 Jul 2024
At a glance
- Drugs Elotuzumab (Primary)
- Indications Myelofibrosis; Polycythaemia vera
- Focus Therapeutic Use
- 27 Jun 2024 Status changed from recruiting to active, no longer recruiting.
- 15 Jun 2023 Results (as of Feb 14, 2023, n=11), presented at the 28th Congress of the European Haematology Association
- 14 Dec 2021 2 participants had been enrolled so far in this trial as per trial design presented at the 63rd American Society of Hematology Annual Meeting and Exposition